Imunofan® (Imunofan®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceArginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginineArginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine
Similar drugsTo uncover
  • Imunofan®
    spray nazal. 
    BIONOKS NPP, LLC     Russia
  • Imunofan®
    solution w / m PC 
    BIONOKS NPP, LLC     Russia
  • Imunofan®
    suppositories rect. 
    BIONOKS NPP, LLC     Russia
    • Dosage form: & nbspnasal dosing spray
    Composition:1 dose contains arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine 50 μg, and Excipients (glycine 5 mg, sodium chloride 0.7 mg, benzalkonium chloride 0.014 mg, disodium edetate 0.007 mg, water purified to 0.14 ml)
    Description:

    Transparent or slightly opalescent colorless, or slightly yellowish liquid. A weak specific odor is allowed.

    Pharmacotherapeutic group:Immunomodulating agent
    ATX: & nbsp

    L.03.A.X   Other immunostimulants

    Pharmacodynamics:

    The drug has an immunoregulatory, detoxicating, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. Pharmacological action is based on the achievement of three main effects: correction of the immune system, restoration of the balance of the oxidative-antioxidant reaction of the organism and inhibition of multiple drug resistance mediated by proteins of the transmembrane transport pump of the cell.

    Pharmacokinetics:

    The drug begins to develop within 2 to 3 hours (fast phase) and lasts up to 4 months (medium and slow phases).

    During the fast phase (duration of 2 to 3 days), detoxification is manifested, antioxidant defense of the body is enhanced by stimulation of the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes lipid peroxidation, inhibits the disintegration of phospholipids by cellular membranes and synthesis of arachidonic acid, followed by a decrease in blood cholesterol and production of inflammatory mediators. With toxic and infectious liver damage, the drug prevents cytolysis; reduces the activity of transaminases and the level of bilirubin in the blood serum.

    During the middle phase (beginning 2-3 days, duration up to 7-10 days) there is an intensification - the reactions of phagocytosis and the death of intracellular bacteria and viruses.

    During the slow phase (begins to develop for 7 - 10 days, duration of up to 4 months), immunoregulatory the action of the drug is the restoration of the disturbed parameters of cellular and humoral immunity.During this period, the restoration of the immunoregulatory index is observed, an increase in the production of 5 specific antibodies is noted. The effect of the drug on the production of specific antiviral and antibacterial antibodies is equivalent to the action of therapeutic vaccines. Unlike the latter, the drug does not. significant effect on the production of reactive antibodies of the class IgE and does not enhance the immediate-type hypersensitivity reaction. Imunofan stimulates education IgA with his congenital insufficiency.

    Imunofan effectively suppresses the multiple drug resistance of tumor cells and increases their sensitivity to the action of chemotherapeutic drugs.

    Indications:Applied in adults and children older than 2 years for prevention and treatment of immunodeficient and toxic states, acute and chronic infectious and inflammatory diseases.
    Contraindications:

    Hypersensitivity, children under 2 years.

    Pregnancy and lactation:Do not use the drug in pregnancy, complicated by Rh-conflict. During pregnancy, and during the period of breast-feeding are used only in the case,if the intended use for the mother exceeds the potential risk to the fetus and the baby.
    Dosing and Administration:

    Intranasally. When using the bottle, hold it upright with a spray gun. Remove the protective cap from the sprayer.

    Before the first use, fill the dosing pump by pressing on a wide rim of the sprayer 3-4 times. Insert the nebulizer into the nasal passage with the vertical position of the head. Press the wide rim of the spray gun one time: until it stops. In one dose of the drug contains 50 mcg imunofana. The daily dose should not exceed 200 mcg.

    In the complex therapy of acute and chronic Infectious-inflammatory diseases, accompanied by symptoms of intoxication and immunodeficiency, imunofan appointed by 1 dose (50 μg) in each nasal passage 2 times a day, daily for 10 to 15 days.

    For opportunistic infections (cytomegalovirus and herpetic infection, toxoplasmosis, chlamydia, pneumocystis, cryptosporidiosis): 1 dose (50 mcg) in each nasal passage 2 times a day, daily, treatment course 10 -15 days. If necessary, it is possible to repeat the course in 2-4 weeks.

    In chronic viral hepatitis and chronic brucellosis: 1 dose (50 mcg) in each nasal passage 1 time per day, daily, treatment course-10 - 15 days, in order to prevent recurrence, repeat courses should be conducted after 4-6 months.

    In the scheme of treatment of patients with HIV infection: by 1 dose (50 μg) in each nasal passage 1 time per day, daily, for 10-15 days. If necessary, it is possible to repeat the course in 2-4 weeks.

    In the treatment of cancer patients in the scheme of radical combined treatment (chemoradiotherapy and surgery): 1 dose (50 mcg) in each nasal passage 1 time per day, daily, for 8-10 days before chemoradiotherapy and surgery, followed by continuation of the course throughout the treatment period.

    In patients with a common tumor process (III - IV stage) of different localization in terms of complex or symptomatic therapy: 1 dose (50 mcg) in each nasal passage 1 time per day, daily, for 8-10 days. If necessary and the presence of severe toxicosis is recommended to re-conduct the course.

    Side effects:Individual intolerance is possible.
    Interaction:Increases the effectiveness of other types of drug therapy: the use of imunofana helps to overcome resistance to glucocorticosteroid therapy.The administration of imunofan is possible in combination with steroidal and non-steroidal anti-inflammatory drugs.
    Special instructions:As a result of the activation of phagocytosis, a short-term exacerbation of the foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.
    Effect on the ability to drive transp. cf. and fur:The drug does not affect the ability to manage vehicles, mechanisms.
    Form release / dosage:Spray nasal dosed with 50 mcg / dose.
    Packaging:40 doses in plastic bottles with a capacity of 10 ml. Bottles are sealed lids equipped with a dispensing pump with a plastic casing, a nozzle and a protective cap or similar dosing device. One bottle together with the instruction for use is placed in a pack of cardboard.
    Storage conditions:In the dark place at a temperature of 2 ° C to 10 ° C. Keep out of the reach of children.
    Shelf life:

    2 years. Do not use the product after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-002646
    Date of registration:01.12.2011 / 14.05.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:BIONOKS NPP, LLC BIONOKS NPP, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp06.11.2017
    Illustrated instructions
      Instructions
      Up